Atara Biotherapeutics (ATRA) Operating Expenses (2013 - 2026)

Atara Biotherapeutics' Operating Expenses history runs 14 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• Quarterly Operating Expenses fell 93.45% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.4 million (down 86.18% YoY) and the FY2025 annual result came in at $84.9 million, down 60.02% from the prior year.
• Operating Expenses was $3.9 million for Q1 2026 at Atara Biotherapeutics, down from $4.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $95.5 million in Q1 2022 and bottomed at $3.9 million in Q1 2026.
• A 5-year average of $54.7 million and a median of $61.9 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses grew 16.79% — and 2026, when it sank 93.45%.
• Atara Biotherapeutics' Operating Expenses stood at $75.8 million in 2022, then retreated by 15.24% to $64.2 million in 2023, then dropped by 29.99% to $45.0 million in 2024, then sank by 90.75% to $4.2 million in 2025, then decreased by 6.57% to $3.9 million in 2026.
• Business Quant data shows ATRA's Operating Expenses at $3.9 million in Q1 2026, $4.2 million in Q4 2025, and $7.0 million in Q3 2025.